Brief: Qyuns Therapeutics Says Qx027n Obtains Two Clinical Trial Approvals For Copd, Chronic Rhinosinusitis
31/07/2026 16:12
BRIEF-Qyuns Therapeutics Says Qx027n Obtains Two Clinical Trial Approvals For Copd, Chronic Rhinosinusitis July 31 (Reuters) - Qyuns Therapeutics Co Ltd 2509.HK:
QYUNS THERAPEUTICS CO - QX027N OBTAINS TWO CLINICAL TRIAL APPROVALS FOR COPD AND CHRONIC RHINOSINUSITIS
Further company coverage: 2509.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Qyuns Therapeutics
See all newsBrief: QYUNS Therapeutics Posts HY Adjusted Profit Of RMB202.5 MLN
Brief: Qyuns Therapeutics Says Qx027n Obtains Two Clinical Trial Approvals For Copd, Chronic Rhinosinusitis
Brief: Qyuns Therapeutics Says Saifu Juli To Buy 34% Of Cellularforce For RMB86.02 Million
Brief: Qyuns Therapeutics Repurchases 3.43 Million Shares As Treasury Shares From Nov 6, 2025 To June 9
Brief: Qyuns Therapeutics Co Receives Milestone Payment From Roche